Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, University Hospital of the Universities of Giessen and Marburg UKGM, Justus Liebig University Giessen, Feulgenstr. 12, 35392, Giessen, Germany.
BMC Cancer. 2018 May 4;18(1):527. doi: 10.1186/s12885-018-4433-3.
This systematic review aimed to gather evidence from research on the current state of liquid biopsy in medical practice, specifically focusing on mutation detection and monitoring.
A systematic search was performed via Medline.
The results of this investigation indicate that liquid biopsy plays a critical role in the detection and management of tumors. This technique gives healthcare providers the ability to gather critical and reliable information that may potentially shape the diagnosis, treatment, and prognosis of a variety of cancers in the near future. This study further reveals that liquid biopsy has several potential shortcomings that may limit its application and use in the healthcare setting. Nevertheless, liquid biopsy remains a valuable tool that is gradually becoming a part of routine healthcare practice in oncology departments and hospitals worldwide.
The evidence described herein reveals the potential relevance of liquid biopsy as an important prognostic, diagnostic, and theranostic tool. This non-invasive procedure enables healthcare practitioners to detect and monitor genomic alterations and will likely replace tumor tissue biopsy as the standard method for detecting and monitoring mutations in the future. The information obtained herein can enable physicians to make informed decisions regarding current treatment options; however, liquid biopsy has not yet been incorporated into routine clinical diagnostics for cancer patients.
本系统评价旨在收集医学实践中液体活检现状的研究证据，特别是侧重于突变检测和监测。
通过 Medline 进行系统检索。
本研究结果表明，液体活检在肿瘤的检测和管理中具有重要作用。该技术使医疗保健提供者能够收集关键且可靠的信息，这些信息可能会在不久的将来影响各种癌症的诊断、治疗和预后。本研究进一步揭示了液体活检存在一些潜在的局限性，可能限制其在医疗保健环境中的应用。然而，液体活检仍然是一种有价值的工具，它正在逐渐成为全球肿瘤学部门和医院常规医疗保健实践的一部分。
本文所述的证据表明液体活检作为一种重要的预后、诊断和治疗监测工具具有潜在的相关性。这种非侵入性的检测方法使医疗保健从业者能够检测和监测基因组的改变，并且可能会在未来取代肿瘤组织活检成为检测和监测突变的标准方法。本文所获得的信息可以使医生能够对当前的治疗方案做出明智的决策；然而，液体活检尚未被纳入癌症患者的常规临床诊断。
